BET Bromodomain Inhibition Synergizes with PARP Inhibitor in Epithelial Ovarian Cancer

BET Bromodomain Inhibition Synergizes with PARP Inhibitor in Epithelial Ovarian Cancer

Summary: PARP inhibition is known to be an effective clinical strategy in BRCA mutant cancers, but PARP inhibition has not been applied to BRCA-proficient tumors. Here, we show the synergy of BET bromodomain inhibition with PARP inhibition in BRCA-proficient ovarian cancers due to mitotic catastroph...

Full description

Bibliographic Details
Main Authors:	Sergey Karakashev, Hengrui Zhu, Yuhki Yokoyama, Bo Zhao, Nail Fatkhutdinov, Andrew V. Kossenkov, Andrew J. Wilson, Fiona Simpkins, David Speicher, Dineo Khabele, Benjamin G. Bitler, Rugang Zhang
Format:	Article
Language:	English
Published:	Elsevier 2017-12-01
Series:	Cell Reports
Online Access:	http://www.sciencedirect.com/science/article/pii/S221112471731762X

Similar Items

BET Bromodomain Inhibition Promotes Anti-tumor Immunity by Suppressing PD-L1 Expression
by: Hengrui Zhu, et al.
Published: (2016-09-01)

BET bromodomain inhibitor HMBA synergizes with MEK inhibition in treatment of malignant glioma
by: Elisa Funck-Brentano, et al.
Published: (2021-01-01)

Targeting CARM1 in ovarian cancer with EZH2 and PARP inhibitors
by: Sergey Karakashev, et al.
Published: (2020-07-01)

Selective inhibition of BET bromodomains.
by: Filippakopoulos, P, et al.
Published: (2010)

Selective inhibition of BET bromodomains.
by: Filippakopoulos, P, et al.
Published: (2010)

Developing chemical probes for the BET bromodomains
by: Hewings, D, et al.
Published: (2012)

Chemical probes for bromodomains outside the BET family
by: Brennan, P, et al.
Published: (2013)

Repurposing Pan-HDAC Inhibitors for ARID1A-Mutated Ovarian Cancer
by: Takeshi Fukumoto, et al.
Published: (2018-03-01)

BET bromodomain proteins regulate enhancer function during adipogenesis
by: Brown, Jonathan D., et al.
Published: (2018)

Inhibition of BET bromodomain targets genetically diverse glioblastoma.
by: Cheng, Z, et al.
Published: (2013)

Interactome rewiring following pharmacological targeting of BET bromodomains
by: Lambert, J-P, et al.
Published: (2018)

Inhibition of BET Bromodomain Targets Genetically Diverse Glioblastoma
by: Cheng, Z, et al.
Published: (2013)

Chemical probes and inhibitors of bromodomains outside the BET family
by: Moustakim, M, et al.
Published: (2016)

Discovery of BET bromodomain inhibitors and their role in target validation
by: Mueller, S, et al.
Published: (2014)

Bromodomain Blockade for Intimal Hyperplasia — A Good BET?
by: Allison C. Ostriker, et al.
Published: (2015-11-01)

Immunogenicity of prostate cancer is augmented by BET bromodomain inhibition
by: Wendy Mao, et al.
Published: (2019-10-01)

Potent antimyeloma activity of the novel bromodomain inhibitors I-BET151 and I-BET762.
by: Chaidos, A, et al.
Published: (2014)

BET bromodomain ligands: Probing the WPF shelf to improve BRD4 bromodomain affinity and metabolic stability
by: Jennings, L, et al.
Published: (2018)

Evaluation of linker length effects on a BET bromodomain probe
by: Traquete, R, et al.
Published: (2019)

BET Bromodomain Inhibitors: Novel Design Strategies and Therapeutic Applications
by: Kenneth K. W. To, et al.
Published: (2023-03-01)

Metabolic rewiring in MYC-driven medulloblastoma by BET-bromodomain inhibition
by: Vittoria Graziani, et al.
Published: (2023-01-01)

BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc
by: Delmore, Jake E., et al.
Published: (2014)

Benzodiazepines and benzotriazepines as protein interaction inhibitors targeting bromodomains of the BET family.
by: Filippakopoulos, P, et al.
Published: (2012)

Effect of BET missense mutations on bromodomain function, inhibitor binding and stability
by: Lori, L, et al.
Published: (2016)

Synthesis and biological investigation of (+)-JD1, an organometallic BET bromodomain inhibitor
by: Hassell-Hart, S, et al.
Published: (2019)

RVX-208, an inhibitor of BET transcriptional regulators with selectivity for the second bromodomain.
by: Picaud, S, et al.
Published: (2013)

The design and synthesis of 5-and 6-isoxazolylbenzimidazoles as selective inhibitors of the BET bromodomains
by: Hay, D, et al.
Published: (2013)

RVX-208, an inhibitor of BET transcriptional regulators with selectivity for the second bromodomain
by: Picaud, S, et al.
Published: (2013)

Benzodiazepines and benzotriazepines as protein interaction inhibitors targeting bromodomains of the BET family
by: Filippakopoulos, P, et al.
Published: (2012)

Bioactivation of Isoxazole-Containing Bromodomain and Extra-Terminal Domain (BET) Inhibitors
by: Noah R. Flynn, et al.
Published: (2021-06-01)

Bromodomain and extraterminal (BET) proteins: biological functions, diseases, and targeted therapy
by: Zhi-Qiang Wang, et al.
Published: (2023-11-01)

Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer
by: Shu, Shaokun, et al.
Published: (2017)

BET Bromodomain Blockade Mitigates Intimal Hyperplasia in Rat Carotid Arteries
by: Bowen Wang, et al.
Published: (2015-11-01)

Bromodomain and extra-terminal domain (BET) proteins regulate melanocyte differentiation
by: Archit Trivedi, et al.
Published: (2020-03-01)

Effect of BET Missense Mutations on Bromodomain Function, Inhibitor Binding and Stability.
by: Laura Lori, et al.
Published: (2016-01-01)

Resistance to BET Bromodomain Inhibitors Is Mediated by Kinome Reprogramming in Ovarian Cancer
by: Alison M. Kurimchak, et al.
Published: (2016-08-01)

Bromodomain and Extra-Terminal (BET) Domain Protein Inhibitors for Solid Tumor Cancers
by: Martin V. Nguyen, et al.
Published: (2020-02-01)

Reprogramming by De-bookmarking the Somatic Transcriptional Program through Targeting of BET Bromodomains
by: Zhicheng Shao, et al.
Published: (2016-09-01)

Bipolar Tumor-Associated Macrophages in Ovarian Cancer as Targets for Therapy
by: Vijayalaxmi Gupta, et al.
Published: (2018-09-01)

PFI-1, a highly selective protein interaction inhibitor, targeting BET Bromodomains.
by: Picaud, S, et al.
Published: (2013)